Search clinical trials for: BI 10773 single rising dose

Total 811 results

Pfizer

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

Hepatic Impairment

United States
MedImmune LLC
Amgen

Completed

A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma

Asthma

Poland
ImmuneMed, Inc.

Completed

Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)

Healthy Volunteers

Australia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Healthy | Diabetes Mellitus, Type 2

United States
Boehringer Ingelheim

Completed

A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects

Diabetes Mellitus, Type 2

Austria, Germany, Italy
Boehringer Ingelheim

Completed

Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration

Diabetes Mellitus, Type 1

Canada
GlaxoSmithKline

Completed

Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™

Streptococcus Pneumoniae Vaccines | Infections, Streptococcal

Mexico
Newsoara Biopharma Co., Ltd.

Recruiting

Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects

T2DM (Type 2 Diabetes Mellitus)

China
Hanmi Pharmaceutical Company Limited

Completed

Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers

Rheumatoid Arthritis

Netherlands
Nanjing Immunophage Biotech Co., Ltd
Novotech (Australia) Pty Limited

Not yet recruiting

A Study of Orally Administered IPG7236 in Healthy Adult Participants

Atopic Dermatitis

Australia
Boehringer Ingelheim

Completed

Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function

Hepatic Insufficiency | Healthy

Romania
7 Hills Pharma, LLC
Frontage Clinical Services, Inc.

Completed

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

Solid Tumor

United States
XOMA (US) LLC

Completed

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery (XOMA 358)

Hypoglycemia

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Healthy
Pfizer

Completed

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Healthy Subjects

Belgium
OliPass Corporation

Completed

OLP-1002 is Being Studied in the Treatment of Pain.

Pain

United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Obesity | Diabetes Mellitus, Type 2

United States, Belgium, Bulgaria, Colombia, Czech Republic, Finland, France, Germany, Guatemala, Mexico, Peru, Russian Federation, Spain, Ukraine
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Diabetes Mellitus, Type 2 | Renal Insufficiency

United States, Canada, France, Hong Kong, India, Malaysia, Netherlands, Philippines, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, United Kingdom
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

Diabetes Mellitus, Type 2

Germany
Pfizer

Completed

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Healthy Subjects

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Hypertension | Diabetes Mellitus, Type 2

United States, Canada, Czech Republic, Denmark, Estonia, Finland, France, Germany, Lebanon, Netherlands, Norway, Sweden
Boehringer Ingelheim

Completed

Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers

Healthy
Fuji Yakuhin Co., Ltd.

Completed

Single Dose Phase I Study of FYU-981

Healthy

Japan
Nutrition Institute, Slovenia
MEDEDUS, Ljubljana, Slovenia; Vizera d.o.o.; Valens Int. d.o.o., Slovenija

Completed

Bioavailability Study of CoQ10 Formulations in Healthy Elderly Adults (CoQ10-01)

Bioavailability of Coenzyme Q10

Slovenia
Pulmocide Ltd

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945

Aspergillosis

United Kingdom
Juno Therapeutics, a Subsidiary of Celgene

Active, not recruiting

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Follicular Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Mantle-cell Lymphoma

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Healthy

United States
Presidio Pharmaceuticals, Inc.
Boehringer Ingelheim

Completed

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

United States
GlaxoSmithKline

Completed

To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944

Infections, Bacterial

United States
Boehringer Ingelheim

Completed

Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers

Healthy
Rockefeller University
University of Cologne

Completed

A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074

Healthy | HIV

Germany, United States
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Hospital-Acquired Pneumonia

Pneumonia
Chong Kun Dang Pharmaceutical

Completed

Evaluation of the Safety and Tolerability of CKD-510 in Healthy Subjects

Healthy Volunteers

France
Jiangsu Sinorda Biomedicine Co., Ltd

Completed

Single-dose and Multiple-dose X842 Phase 1 Study

Healthy Volunteers

China
National and Kapodistrian University of Athens

Unknown

Single Dose of Tranexamic Acid and Blood Loss, in Elderly Patients With Hip Fracture

Hip Fractures | Blood Loss, Surgical | Complication, Postoperative

Greece
Enterome
Quotient Clinical

Completed

First-in-Human Single and Multiple Dose of EB8018

Healthy Volunteers

United Kingdom
Jair Bar, M.D., Ph.D.
Merck Sharp & Dohme LLC

Completed

Anti PD-1 Neo-adjuvant Treatment for NSCLC (MK3475-223)

Non Small Cell Lung Carcinoma | Stage II | Stage I

Israel
Contrad Swiss SA

Completed

Evaluation of the "ST500 SINGLE- DOSE GEL" in Patients With Symptomatic Long Head of the Biceps Tendon Injury

Long Head of Biceps Rupture

Italy
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1690

Healthy

Belgium
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Diabetes Mellitus, Type 2

United States, Canada, Greece, India, Philippines, Thailand, Ukraine
Daewoong Bio Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects

Dry Eye Syndromes

Korea, Republic of
TRB Chemedica International SA

Not yet recruiting

Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease (BUSTON-01)

Dry Eye Disease
TRB Chemedica International SA

Not yet recruiting

Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease (BUSTON-02)

Dry Eye Disease
Galapagos NV
MorphoSys AG

Completed

First in Human of Single and Multiple Doses of MOR106

Healthy | Dermatitis, Atopic

Belgium, Hungary, Moldova, Republic of, Romania
OSE Immunotherapeutics
Boehringer Ingelheim

Active, not recruiting

A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Solid Tumor, Adult

France, Belgium
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
Acerus Pharmaceuticals Corporation

Completed

PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women

Female Sexual Dysfunction

United States
Xi'an Xintong Pharmaceutical Research Co.,Ltd.

Recruiting

Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects (XT1061)

Chronic Hepatitis b

China

3

Subscribe